Late-onset isavuconazole-induced liver injury

Felix Bongomin; Isabel Rodriguez-Goncer; Carol Lorden; Akaninyene Otu; Rohit Bazaz

doi:10.1016/j.mmcr.2018.07.006

Late-onset isavuconazole-induced liver injury

Med Mycol Case Rep. 2018 Jul 19:22:11-13. doi: 10.1016/j.mmcr.2018.07.006. eCollection 2018 Dec.

Authors

Felix Bongomin^{1

2}, Isabel Rodriguez-Goncer¹, Carol Lorden¹, Akaninyene Otu¹, Rohit Bazaz¹

Affiliations

¹ The National Aspergillosis Centre, ECMM Centre of Excellence in Clinical and Laboratory Mycology and Clinical Studies, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK.
² Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK.

Abstract

Antifungal agents account for approximately 3% of Drug-Induced Liver Injury (DILI) cases. Isavuconazole is a novel triazole, and experience with long-term use of it is lacking. We report a case of late-onset DILI occurring after 11 months of isavuconazole therapy in a 55-year old man of Angolan descent on long-term antifungal therapy for the management of chronic pulmonary aspergillosis complicating previously treated pulmonary tuberculosis. The DILI could be described as idiosyncratic as it was not associated with high isavuconazole serum levels and his liver function tests returned to normal following treatment discontinuation.

Keywords: Chronic pulmonary aspergillosis; Drug-induced liver injury; Isavuconazole; Late-onset.

Publication types

Case Reports